An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IMV Inc. to Present at Two Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
IMV Inc. (NASDAQ: IMV) announced participation in two significant events: the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, featuring presentations and one-on-one investor meetings, and the Wells Fargo Biotech Forum on April 12-13, 2022, focused on one-on-one investor meetings. IMV's lead therapy, maveropepimut-S, is in clinical trials for various cancers. The Needham conference presentation will be available for replay on the company's website for 90 days.
Positive
None.
Negative
None.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in the 21st Annual Needham Virtual Annual Healthcare Conference, which will be held April 11-14, and the Wells Fargo Biotech Forum, which will be held April 12-13.
21st Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetings
Date: Thursday April 14, 2022 Time: 12:45 p.m. ET Webcast: Click Here
Wells Fargo Biotech Forum Format: One-on-one investor meetings
Date: April 12-13
IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX™ technology. Through a differentiated mechanism of action, the DPX platform delivers instructions to the immune system and generates a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S) delivers antigenic peptides of survivin, a well-recognized cancer antigen. Treatments with MVP-S have demonstrated the activation of a targeted and sustained anti-tumor immune response, correlated with clinical benefit and have been well tolerated across all clinical trials. MVP-S is currently being evaluated in clinical trials for blood and solid cancers, including in Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer was initiated in early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the potential impact of the VITALIZE study and the anticipated date data from such study is available, the Company’s ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the Company’s expected timeline associated with its cash runway; the Company’s priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as others risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.
What conferences is IMV participating in April 2022?
IMV is participating in the 21st Annual Needham Virtual Healthcare Conference on April 14 and the Wells Fargo Biotech Forum on April 12-13, 2022.
When will IMV's presentation be available for replay?
The presentation from the 21st Annual Needham Virtual Healthcare Conference will be available for replay on IMV's website for 90 days.
What is IMV's lead therapy and what cancers is it targeting?
IMV's lead therapy is maveropepimut-S (MVP-S), which is being evaluated in clinical trials for blood and solid tumors, including Diffuse Large B Cell Lymphoma, ovarian, bladder, and breast cancers.
What is the format of the Needham Healthcare Conference for IMV?
The format includes a presentation and one-on-one investor meetings on April 14, 2022.
What type of immunotherapy is IMV developing?
IMV is developing immune-educating therapies based on its DPX platform, targeting specific immune responses for cancer treatment.
